Eisai/Biogen’s Leqembi Will Launch Below Aduhelm At $26,500 Per Year
Available For Commercially Insured Patients By Mid-Month
With accelerated approval granted and a supplemental filing for full approval in the FDA's hands, Eisai set a price it says is below the “societal value” its Alzheimer’s drug provides as it prepares to seek Medicare coverage. Labeling notably comes with no black box warning or safety restrictions despite various concerns.
